Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Cerevel Therapeutics

Cerevel Therapeutics

Cerevel Therapeutics is a Boston-based biopharmaceutical company.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies. The company was founded through a partnership with Pfizer and Bain Capital.

Cerevel Therapeutics is committed to unraveling the mysteries of the brain in treating neuroscience diseases. The company has a diversified pipeline that comprises five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a wide range of neuroscience diseases that includes Parkinson’s, epilepsy, schizophrenia, and substance use disorder.

Cerevel Therapeutics is making its current research and development programs, and the company is exploring new modalities via internal research efforts, external collaborations, or potential acquisitions.

Timeline

May 4, 2021
Cerevel Therapeutics appoints Scott M. Akamine as Chief Legal Officer.

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Nick Paul
June 30, 2021
FierceBiotech
Cerevel Therapeutics' schizophrenia prospect has impressed in a phase 1b clinical trial, triggering a 136% surge in the stock price. The Pfizer spinout is now preparing to move into phase 2 and looking into additional indications including dementia-related psychosis.
BioSpace
May 4, 2021
BioSpace
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced the appointment of Scott M. Akamine as chief legal officer, effective May 24, 2021.
BioSpace
April 21, 2021
BioSpace
Cerevel Therapeutics , a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Abraham N. Ceesay to the newly-created role of president, effective May 3, 2021. Mr. Ceesay brings nearly two decades of healthcare experience leading operations at a number of biopharmaceutical companies, serving most recently as chief executive officer at Tiburio Therapeutics
Heather McKenzie
November 13, 2020
BioSpace
Emerging biotech companies have been finding creative ways to explode onto the stock exchange during the COVID-19 pandemic.

References

Golden logo
By using this site, you agree to our Terms & Conditions.